Asio Capital LLC Purchases 11,422 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Asio Capital LLC significantly increased its stake in Thermo Fisher Scientific, acquiring an additional 11,422 shares, resulting in a total of 11,969 shares valued at approximately $4.85 million.
• Major investors, including Nuveen LLC and UBS AM, have also increased their positions, indicating strong institutional interest in the company.
• Thermo Fisher Scientific's recent earnings report showed an EPS of $5.36, exceeding analysts' expectations, and the company also declared a quarterly dividend of $0.43 per share.

Asio Capital LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2,088.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,969 shares of the medical research company's stock after acquiring an additional 11,422 shares during the quarter. Asio Capital LLC's holdings in Thermo Fisher Scientific were worth $4,853,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of TMO. Nuveen LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $532,360,000. Sarasin & Partners LLP bought a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $242,991,000. EdgePoint Investment Group Inc. bought a new position in shares of Thermo Fisher Scientific during the 1st quarter worth approximately $172,139,000. Cohen Investment Advisors LLC increased its stake in Thermo Fisher Scientific by 6,655.5% during the 1st quarter. Cohen Investment Advisors LLC now owns 336,156 shares of the medical research company's stock valued at $167,271,000 after purchasing an additional 331,180 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Thermo Fisher Scientific by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock valued at $1,368,859,000 after purchasing an additional 329,974 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 400 shares of the firm's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock worth $14,182,963 over the last 90 days. 0.33% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TMO. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $490.00 to $550.00 in a report on Thursday, September 11th. Evercore ISI dropped their price objective on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. William Blair initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating on the stock. Finally, UBS Group upped their price objective on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $588.35.

Thermo Fisher Scientific Stock Down 0.5%

Shares of NYSE TMO opened at $461.95 on Tuesday. The company's 50-day simple moving average is $477.84 and its 200-day simple moving average is $446.71. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $620.00. The firm has a market cap of $174.44 billion, a price-to-earnings ratio of 26.72, a price-to-earnings-growth ratio of 2.52 and a beta of 0.75. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business earned $5.37 earnings per share. The company's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.